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Abstract
Somatostatin receptor scintigraphy (SRS) has become a rou-
tine imaging method for the diagnostics of neuroendocrine tu-
mours (NET). 99mTc-EDDA/HYNIC-octreotate (Polatom, Poland)
is a new radiotracer with high affinity for SSTR2 and similar phys-
iological biodistribution to 111In-Octreoscan.
We present a case of a 47-year-old man with disseminated
duodenal carcinoid. The patient had been operated due to the
tumour mass detected in pancreatic head area. Histopatholo-
gy revealed carcinoid of the duodenal wall with local lymph node
and liver metastases. The patient was qualified for chemothe-
rapy stopped due to severe leucopenia. 99mTc EDDA/HYNIC-
-octreotate scintigraphy was performed for staging and to de-
termine SSTR status of the tumour before planned 90Y-DOTA-
TATE therapy. The multiple metastatic lesions were detected
all over the body. The high quality images with high target/non
target ratio were obtained. 99mTc-MDP scintigraphy confirmed
multiple bone metastases. On the basis of SRS result the pa-
tient was qualified for 90Y-DOTA-TATE therapy. In conclusion,
99mTc EDDA/HYNIC-octreotate can be regarded as a promising
tracer for staging and to determine SSTR status of NET.
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Case report
Somatostatin receptor scintigraphy (SRS) has become a rou-
tine diagnostic procedure in the diagnostics of neuroendocrine
tumours (NET). 99mTc labelled somatostatin analogues with spe-
cific and high receptor affinity and good biodistribution have been
searched for. 99mTc-EDDA/HYNIC-octreotate (Polatom, Otwock-
-wierk, Poland) is a new radiotracer with a high affinity for SSTR2
(somatostatin type receptor 2), which shows promising proper-
ties for detecting and staging NET [14]. Octreotate differs from
octreotide by the more hydrophilic tyrosine in the third position
and the terminal threonine. Physiological biodistribution of the tracer
is similar to 111In-Octreoscan but allows rapid imaging and detects
more metastatic lesions with higher target/non-target ratios [4].
A 47-year-old man without a significant past medical history
developed progressive dyspeptic symptoms over a few weeks
with concomitant abdominal pain and weight loss. On physical
examination there was tenderness and palpable mass in the epi-
gastric area. Ultrasound examination showed an epigastric tumour
90 mm in diameter with enlargement of the retroperitoneal lymph
nodes. Computed tomography scan revealed solid mass local-
ized in the pancreatic head area with the lymphadenopathies of
the epigastric area as well as two metastatic tumours within the
5th and 6th segments of the liver. Upper gastrointestinal endosco-
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py identified circular ulceration with an infiltration of the duodenal
wall above the major duodenal papilla. Multiple surface biopsies
of the infiltration, as well as USG-guided fine needle aspiration
biopsies of the tumour, did not reveal neoplasmatic cells. An ex-
ploratory laparotomy revealed solid tumour infiltrating the duode-
num. Intraoperative ultrasonography showed metastases in both
lobes of the liver. Whipple pancreatoduodenectomy was performed
and histopathology revealed carcinoid of the duodenal wall with
metastases to the regional lymph nodes. After recovery, the patient
was qualified for the palliative chemotherapy with streptozocin
(Zanosar, Upjohn, Kalamazoo, USA) and 5-fluorouracil. After 4 se-
ries of chemotherapy the treatment was stopped because of leu-
copenia, and the patient was referred to a Nuclear Medicine Unit
for SRS. 99mTc EDDA/HYNIC-octreotate scintigraphy was performed
for staging and to determine the SSTR status of the tumour.
Abdominal SPECT and whole body scintigraphy with 99mTc-
-HYNIC-octreotate (740 MBq) were performed. A dual-head, large
view field E.CAM gamma camera (Siemens, Erlangen, Germany)
equipped with low-energy, high resolution (LEHR) collimators with
an e.soft operating system was used. A whole-body scan in the
anterior and posterior projections (256 × 1024 matrix, 6 cm/min)
was performed 10 min, 4 h and 24 h after i.v. injection. The SPECT
study was performed 4 h after tracer injection using a 360° orbit
(180° for each head), step and shoot mode, at 30 s per view.
Focal tracer accumulation was considered to be specific when
visualised on both 4 h and 24 h scans. Semi-quantitative region of
interest (ROI) analysis of the metastatic lesions was performed
and the target/non-target ratios were assessed. 99mTc-MDP bone
scintigraphy was performed in the routine manner.
High quality images were obtained with multiple metastatic
lesions visible all over the body (Figure 1A). The highest target/
/non-target ratio was obtained 4 h post injection (liver3:1, lung
2,8:1, bone6,8:1). 99mTc-MDP scintigraphy two weeks later con-
firmed multiple bone metastases (Figure 1B). On the basis of SRS
result the patient was qualified for 90Y-DOTA-TATE therapy.
Conclusions
99mTc EDDA/HYNIC-octreotate can be regarded as a very
promising radiopharmaceutical for detecting and staging NET. It
detects SSTR positive tissue with a high target/non-target ratio.
Dissemination detected with 99mTc EDDA/HYNIC-octreotate can
be an indication for 90Y-DOTA-TATE therapy. Fast (4 h p.i.) tumour
visualisation is expected to significantly simplify this procedure
for patients and hospital schedules in comparison to 111In-Oc-
treoscan imaging. The presented case report suggests that sev-
eral biopsies can fail to confirm the NET tumour. According to the
literature in such cases diagnosis can be based on clinical symp-
toms, combined with radiological and scintigraphic findings [5].
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Figure 1A. 99mTc-EDDA/HYNIC-octreotate images; B. 99mTc-MDP images.
